| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7946ec4f3ab0ccdf6d369bf5079567ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_524c7f5e9a17b9c3b2578015c4debbba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2498aa347a26e07c004138cbd16f0635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a861e5945646db8b327620c99cf78115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2bcd78a67d4071e7b4d80a23dde752f |
| publicationDate |
2008-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1976885-A2 |
| titleOfInvention |
Pharmaceutical antibody compositions with resistance to soluble cea |
| abstract |
The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence 'SYWMH' and a CDR-H2 having the amino acid sequence 'FIRNKANGGTTEYAASVKG' and a CDR-H3 having the amino acid sequence 'DRGLRFYFDY' or (ii) a CDR-H 1 having the amino acid sequence 'TYAMH' and a CDR-H2 having the amino acid sequence 'LISNDGSNKYYADSVKG' and a CDR-H3 having the amino acid sequence 'DRGLRFYFDY'. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed. |
| priorityDate |
2005-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |